Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676500 | 1.00 | ABCC4 (0.38) | ABCC4MAPTALDH1A1LMNAEP300 | |
| SCHEMBL7680072 | 0.81 | — | — | |
| SCHEMBL7558899 | 0.78 | EP300 (0.42) | MAPTLMNAEP300ACLY | |
| SCHEMBL7558903 | 0.78 | EP300 (0.42) | MAPTLMNAEP300ACLY | |
| SCHEMBL3680666 | 0.77 | EP300 (0.32) | EP300ACLY | |
| SCHEMBL5271639 | 0.73 | EP300 (0.62) | MAPTLMNAEP300 | |
| SCHEMBL7124103 | 0.73 | EP300 (0.62) | MAPTLMNAEP300 | |
| SCHEMBL8067161 | 0.73 | F7 (0.50) | MAPTLMNAEP300 | |
| SCHEMBL18803276 | 0.73 | GRIK1 (0.36) | EP300 | |
| SCHEMBL7174689 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324284-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110263653-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-10-27 | — | — | US | disclosed |
| US-7943800-B2 | Migrastatin analogs and uses thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2011-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281916-A1 | MIGRASTATIN ANALOGS AND USES THEREOF | KDR, HMGCR, LPAR3 | ABCC4 1088/4885MAPT 3369/4885ALDH1A1 1123/4885 |
| US-20110263653-A1 | MIGRASTATIN ANALOG COMPOSITIONS AND USES THEREOF | C3AR1, C1R, MRPS18A | ABCC4 495/4885MAPT 3280/4885ALDH1A1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.